Background and History

StageBio is a leading international provider of GLP-compliant research, preclinical and clinical histology, pathology and specimen archiving services for the biopharmaceutical, medical device and contract research.

We formed through the merger of renowned contract research organizations—Histo-Scientific Research Laboratories (HSRL), HSRL Archives, Vet Path Services, Inc. (VPS), VPS Archives, Tox Path Specialists (TPS), Alizée Pathology, and TPL Path Labs of Germany. By integrating these scientific ventures, we are able to offer beginning-to-end histopathology services to meet all of our clients’ needs under one roof.

Team_Header_1440x625-1 Scientist-looking-through-a-microscope-1

Our Commitment to Smart Science

Our offerings include necropsy oversight, clinical pathology analysis, efficacy determination for new compounds and devices, toxicological evaluation of products subject to regulatory approval, medical device pathology, immunohistochemistry, and neuropathology.

StageBio operates several state-of-the-art sites in the United States, plus a laboratory facility in Freiburg, Germany. We have a team of more than 30 board-certified veterinary pathologists and a group of more than 75 technicians and support staff committed to quality, scientific integrity, and client satisfaction.

Team-of-researchers Serious science students working in a laboratory

StageBio Statistics

30 Pathologists
1000 + Clients
9 Locations
250,000 Cubic feet in archiving space
50,000 + Slides produced monthly

Company Values

Long-standing
Long-Standing
Our legacy as industry leaders started in 1999. We have positioned ourselves to be agents of progress, dedicated to the improvement of research technology and medical advancement.
high-preforming
High-Performing
We have hosted several successful FDA audits across multiple sites. We believe in evaluating and assessing our performance standards alongside regulators and clients in order to cultivate excellence.
big-picture
Big-Picture Thinking
We have partnered with international scientific leaders to develop FDA-approved therapies and medical devices because we believe in improving the quality of life of our friends, families, and neighbors.

Meet Our Team

Tom Galati

CEO

Damon Lusk

CFO

Lynn Neff

COO

Sam Jeffrey

Chief of Staff

Carrie Harris

Senior Vice President of Client Relations

Kathy Bailey

Vice President of Corporate Integration

Charles Coffman

Vice President of Corporate Development

Chris Johnson

Client Ambassador

Michael Cerio

Business Development Executive

Charles Brehm

Director of Information Technology

Katherine A.B. Knostman, DVM, PhD, DACVP

Senior Director of Pathology

Mark Butt, DVM, DACVP

Director of Neuropathology

Elizabeth Hutto, DVM, PhD, DACVP

Director of Investigative Pathology

Nicolette Jackson, DVM, MS, DACVP

Director of Medical Device Services

Serge Rousselle, DVM, DACVP

Director of Imaging and Digital Pathology

Joan Wicks, DVM, PhD, DACVP

Director of Exploratory Techniques and Biomarker Development

David Garlick, DVM, DACVP

Distinguished Senior Pathologist

Matthew Buccellato, DVM, PhD, DACVP

Senior Pathologist

Sarah Cramer, DVM, PhD, DACVP

Senior Pathologist

Laura Elcock, DVM, PhD, DACVP

Senior Pathologist

Cindy Farman, DVM, PhD, DACVP

Senior Pathologist

Molly Friedemann, DVM, MS, DACVP

Pathologist

Jessica Hoane, DVM, MTOX, DACVP, DABT

Senior Pathologist

Julie A. Hutt, DVM, PhD, DACVP

Senior Pathologist

Lisa Lanigan, DVM, PhD, DACVP

Senior Pathologist

Juliana Lee, BVSc, MS, DACVP

Senior Pathologist

Sherry Morgan, DVM, PhD, DACVP, DABT, DABVT

Senior Pathologist

April Paulman, DVM, PhD, DACVP

Senior Pathologist

Deepa B. Rao, BVSc, MS, PhD, DABT, DACVP, FIATP

Senior Pathologist

Brett Saladino, DVM, DACVP

Senior Pathologist

Stephanie Shrader, DVM, PhD, DACVP

Senior Pathologist

John M. Sullivan, DVM, PhD, DACVP, DABVT

Senior Pathologist

Jamie K. Young, DVM, PhD, DACVP

Senior Pathologist

Stay Connected

Get the latest StageBio news and updates sent straight to your inbox.

Learn more about StageBio’s COVID-19 response